SEATTLE, March 5 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals,
Inc. (Nasdaq: TRBN), today announced that executives will present an
overview of the company at two March investor conferences:
-- March 10: Sanford Bernstein Biotechnology Conference in Alta, Utah. Dr.
Peter Thompson, president, CEO and chairman, will present to attendees.
-- March 18: Invest Northwest CEO & Investor Forum at the Bell Harbor
International Conference Center, 2211 Alaskan Way, Pier 66 in Seattle,
Wash. Dr. Ken Mohler, co-founder and senior vice president of Research
and Development, is scheduled to present at 11:20 a.m. PDT. The
presentation will be available via audio webcast at
Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy, and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain polypeptide protein, or SMIPtm, therapeutics, and are designed using its custom drug assembly technology. Trubion's lead product candidate, TRU-015, has completed a Phase 2b clinical trial for the treatment of rheumatoid arthritis, and is also in development under the Wyeth collaboration for the treatment of non-Hodgkin's lymphoma, Systemic Lupus Erythematosus and other undisclosed indications.
Trubion's proprietary product candidate, TRU-016, is a novel CD37-targeted therapy for the treatment of B-cell malignancies currently in Phase 1 clinical evaluation. In addition to Trubion's current product candidates, the company is also developing additional alliance and proprietary product candidates that build on its product development experience. More information is available in the investors section of Trubion's website: investors.trubion.com.
Certain statements in this release may constitute "forward-looking
statements" within the meaning of Section 21E of the Securities Exchange
Act of 1934 and Section 27A of the Securities Act of 1933. These statements
include, but are not limited to, those related to the company's future
clinical development programs and the timing thereof, the company's
expected financial and operating results, future clinical development
plans, the details of the clinical trials and the results and timing
thereof, and the timing of regulatory applications and action. These
statements are based on current expectations and assumptions regarding
future events and business performance and involve certain risks and
uncertainties that could cause actual results to differ materially. These
risks include, but are not limited to, risks associated with the company's
Wyeth collaboration, including Wyeth's control over development timelines,
and such other risks as identified in the company's quarterly report on
Form 10-Q for the period ended Sept. 30, 2007, and from time to time in
other reports filed by Trubion with the U.S. Securities and Exchange
Commission. These reports are available on the Investors page of the
company's corporate Web site at http://www.trubion.com. Trubion undertakes
no duty to update any forward-looking statement to conform the statement to
actual results or changes in the company's expectations.
For more information, contact:
Trubion Pharmaceuticals, Inc.
Senior Director, Corporate Communications
Waggener Edstrom Worldwide Healthcare
Senior Vice President
|SOURCE Trubion Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved